The European Medicines Agency (EMA) has officially backed the use of Novo Nordisk's Wegovy, a groundbreaking medication primarily known for weight loss, to aid in the treatment of heart failure associated with obesity. This endorsement published on <a title="Reuters" href="https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-backs-use-novos-wegovy-obesity-related-heart-condition-2024-09-19/">Reuters</a> marks a significant expansion of Wegovy&rsquo;s therapeutic profile, highlighting its potential benefits beyond mere weight management.
Wegovy, which contains the active ingredient semaglutide, is part of the GLP-1 receptor agonist class of drugs. Since its authorization for obesity treatment in the European Union in 2022, it has gained traction for its effectiveness in regulating blood sugar and suppressing appetite. The recent EMA approval focuses on its use for patients suffering from obesity-related heart failure with preserved ejection fraction (HFpEF), a condition characterized by stiff heart muscles that impede blood flow and lead to symptoms such as shortness of breath and swelling.
Clinical data from a late-stage study revealed promising outcomes for patients using Wegovy. After one year of treatment, participants not only experienced significant weight loss but also reported a 16.6-point improvement on a health scale that assessed various heart failure-related criteria. Improvements were also noted in physical limitations and exercise capacity, reinforcing the drug's multi-faceted health benefits.
This development enhances Novo Nordisk's competitive position, particularly against U.S. rival Eli Lilly, whose drug tirzepatide has shown a 38% reduction in heart failure risk in a similar patient population. Novo plans to resubmit Wegovy's efficacy data to the U.S. Food and Drug Administration next year, aiming for approval in the American market.
With the EMA's endorsement, Wegovy is set to play a vital role in addressing the complex interplay between obesity and cardiovascular health, offering hope to many patients struggling with these intertwined conditions.
If you are considering Wegovy for your health goals, get in touch with our certified doctors in the UK for an online consultation at Farmeci. We provide free prescriptions tailored to your needs. If you&rsquo;re looking to <a title="buy Wegovy online" href="https://farmeci.com/onlineclinic/semaglutide-wegovy">buy Wegovy online</a>, you can do so following our prescription.

Novo Nordisk's Wegovy gains EMA approval for treating heart failure linked to obesity, expanding its health benefits beyond weight loss.

EU Approves Wegovy for Heart Failure in Obese Patients

Injections

EU Endorses Novo Nordisk's Wegovy for Heart Failure in Obesity Patients

eu-endorses-wegovy-for-heart-failure-in-obesity-patients

&nbsp;
<span style="color: rgb(224, 62, 45);" data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;An STD called gonorrhea can infect the genitalia, rectum, and throat. It is fairly typical, particularly among young people between the ages of 15 and 24. By engaging in vaginal, anal, or oral intercourse with a person who has gonorrhea, you run the risk of contracting it. Gonorrhea can be passed from a pregnant person to their unborn child during childbirth.&quot;}" data-sheets-userformat="{&quot;2&quot;:513,&quot;3&quot;:{&quot;1&quot;:0},&quot;12&quot;:0}">Please click on Start Assessment below to answer a few short questions so that you can review your treatment options.
&nbsp;

Buy Weight Management Pens at a Fraction of the Price!
<ul>
<li style="font-size: 12pt; font-family: arial, helvetica, sans-serif;">Order from a UK Registered Pharmacy &ndash; Delivered directly from our London location.</li>
<li style="font-size: 12pt; font-family: arial, helvetica, sans-serif;">Fast &amp; Secure Delivery by DHL &ndash; Arrives within 24 hours, shipped cold for maximum freshness.</li>
<li style="font-size: 12pt; font-family: arial, helvetica, sans-serif;">Trusted by Thousands &ndash; Check our Trustpilot <a href="https://uk.trustpilot.com/review/mylondonpharmacy.co.uk">reviews</a>.</li>
</ul>
Delivery is only available to&nbsp;the Netherlands, Germany, the USA,&nbsp;and Switzerland.&nbsp;

Recent research published on <a title="Everyday Health" href="https://www.everydayhealth.com/coronavirus/wegovy-may-reduce-the-risk-of-dying-from-covid/">Everyday Health</a>&nbsp;has revealed surprising findings about Wegovy (semaglutide), a popular weight loss medication. According to a large study, people taking Wegovy for weight loss were 33% less likely to die from COVID-19 compared to those on a placebo. This discovery opens new discussions about the broader health benefits of the drug, beyond weight loss.
The study, which was part of the SELECT trial and presented at the European Society of Cardiology (ESC) Conference in 2024, initially focused on the cardiovascular benefits of Wegovy. Researchers were aiming to see how the drug impacted heart disease, but they found unexpected results related to COVID-19 as well. Over the 3.3-year study, Wegovy reduced the risk of death from both heart disease and COVID-19. While it didn&rsquo;t prevent people from catching the virus, it seemed to help them survive it.
<h2>How Does Wegovy Help in Lowering the Risk of Death From COVID-19?</h2>
While Wegovy is already known to reduce heart attack and stroke risks in people with obesity, researchers are curious about why it also lowered deaths from COVID-19. Experts, including lead study author Dr. Benjamin Scirica from Harvard Medical School, suggest that the benefits may stem from more than just weight loss. There&rsquo;s a possibility that Wegovy improves overall health, positively affecting the kidneys, liver, and possibly even the immune system. This could explain why those on Wegovy experienced fewer severe COVID-19-related issues and deaths.
Dr. Dan Azagury, a bariatric surgeon at Stanford Medicine, supports this theory. He notes that obesity has long been associated with poor COVID-19 outcomes due to fat cells being particularly receptive to the virus. Losing weight with Wegovy may have reduced the likelihood of severe infections, improving survival rates during the pandemic.
<h2>Beyond Weight Loss: A Boost for the Immune System?</h2>
While researchers are still exploring the full scope of Wegovy&rsquo;s effects, the results are promising. The study highlights that people who used the drug had not only a 15% lower risk of heart disease but also a 23% reduction in deaths from other causes, including COVID-19. Whether these effects are tied solely to weight loss or if Wegovy also enhances the immune system remains an exciting area for future research.
For those battling obesity, Wegovy may offer more than just a slimmer figure&mdash;it could improve overall health and even protect against life-threatening conditions like COVID-19.&nbsp;If you're looking to <a title="buy Wegovy for weight loss" href="https://farmeci.com/onlineclinic/semaglutide-wegovy">buy Wegovy for weight loss</a>, get a free prescription from a healthcare provider like us. Start the medication based on your body's suitability for better, positive results.
<div class="flex-shrink-0 flex flex-col relative items-end">
<div>
<div class="pt-0">
<div class="gizmo-bot-avatar flex h-8 w-8 items-center justify-center overflow-hidden rounded-full">&nbsp;</div>
</div>
</div>
</div>

Wegovy May Lower the Risk of Death From COVID-19

wegovy-may-lower-the-risk-of-death-from-covid-19

Recent research published on <a title="Forbes" href="https://www.forbes.com/sites/ariannajohnson/2024/09/11/women-taking-mounjaro-and-zepbound-lose-more-weight-than-men-new-study-suggests-what-to-know/">Forbes</a> has shed light on the effectiveness of Mounjaro (tirzepatide), a prominent medication used for weight loss and diabetes management, revealing intriguing differences between how men and women respond to the treatment. This blog explores these findings and their implications for patients and healthcare providers.
<h2>The Study: Key Findings</h2>
A comprehensive analysis presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) highlighted significant gender differences in weight loss outcomes among individuals taking <a title="tirzepatide" href="https://farmeci.com/onlineclinic/tirzepatide">tirzepatide</a>, marketed as Mounjaro and Zepbound. This analysis, involving 4,677 participants with Type 2 diabetes and obesity, found that women experienced greater weight loss compared to their male counterparts.
Specifically, women lost up to 24.6% of their body weight on average, while men lost up to 18.1%. The study tracked these participants over a period ranging from 72 to 88 weeks and used various doses of tirzepatide to assess its efficacy and safety.
<h2>Why Do Women Lose More Weight on Mounjaro?</h2>
The reason behind this disparity is not fully understood, but several theories offer potential explanations. Hormonal differences between men and women could play a significant role. Research suggests that women generally have higher body fat percentages and different fat distribution compared to men, which might make them more responsive to the weight loss effects of GLP-1 receptor agonists like tirzepatide.
A 2022 study and recent findings in the Journal of the American College of Cardiology support this notion, indicating that women often experience more substantial weight loss with these medications. Additionally, societal factors such as body image pressures might influence women&rsquo;s adherence to lifestyle changes, potentially amplifying the effects of the drug.
<h2>Side Effects: A Gender Comparison</h2>
While the weight loss results are promising, the study also revealed that women reported more common side effects than men. Nausea and vomiting, common side effects of tirzepatide, were experienced by women at rates nearly double those of men. This higher incidence of side effects in women raises questions about the drug's differential impact based on sex.
The increased common side effects in women might be linked to the more pronounced weight loss observed. It&rsquo;s possible that the medication&rsquo;s effects are stronger in women, leading to more intense reactions. However, these side effects are generally transient and tend to improve over time, suggesting that the medication&rsquo;s benefits may outweigh the temporary discomfort for many users.
<h2>Implications for Patients and Healthcare Providers</h2>
For individuals considering to <a title="buy Mounjaro" href="https://farmeci.com/onlineclinic/mounjaro">buy</a><a title="buy Mounjaro" href="https://farmeci.com/onlineclinic/mounjaro"> </a><a title="buy Mounjaro" href="https://farmeci.com/onlineclinic/mounjaro">Mounjaro</a>, these findings emphasize the need for personalized treatment plans. Healthcare providers should be aware of the potential for gender-based differences in both efficacy and side effects. Women might achieve greater weight loss, but they may also experience more frequent or severe side effects, necessitating close monitoring and management.
Patients should discuss their individual health conditions, goals, and potential side effects with their healthcare provider like us at Farmeci to tailor the treatment approach accordingly. For some, the significant weight loss achieved may justify the discomfort associated with side effects, while others might need adjustments or alternative treatments.
<h3>Looking Ahead</h3>
The research into Mounjaro's gender-based effects is ongoing, and further studies are needed to clarify these findings and understand the underlying mechanisms. As the medical community continues to explore these differences, patients can look forward to more personalized and effective treatment strategies.
In conclusion, Mounjaro offers promising results for weight loss and diabetes management, with women showing notably greater weight reduction compared to men. However, the increased incidence of side effects in women highlights the importance of individualized care and ongoing research to optimize treatment outcomes for all patients.
&nbsp;
&nbsp;

EU Endorses Novo Nordisk's Wegovy for Heart Failure in Obesity Patients

Discover

EU Endorses Novo Nordisk's Wegovy for Heart Failure in Obesity Patients

Wegovy May Lower the Risk of Death From COVID-19

Women Experience Greater Weight Loss Than Men on Mounjaro: New Research Insights

About Us

Policies

Help